UK Top 10 News

Stay informed with the latest breaking news from across the UK

ALZ-202, a novel Alzheimer’s treatment developed by NeuroGenix, showed encouraging results in Phase II trials, slowing cognitive decline by 28% in early-stage patients over 18 months compared to placebo.
The drug targets amyloid plaques and tau protein tangles, key Alzheimer’s hallmarks.
Presented at the International Dementia Conference, the findings excited researchers, with lead scientist Dr.
Elena Martinez stating, 'This could redefine early intervention.' However, 12% of participants experienced mild brain swelling, raising safety concerns.
The Alzheimer’s Society welcomed the progress but urged caution, noting high costs and accessibility challenges.
With 900,000 UK dementia cases, demand for effective treatments is urgent.
Phase III trials, involving 2,000 patients globally, begin next year, with regulators fast-tracking review.
Critics, including Dr.
James Patel, argue long-term efficacy and side effect management need clarity.
Patients like Sarah Thompson, 62, part of the trial, report improved memory recall, fueling optimism.
The drug could reach markets by 2028 if approved, potentially transforming care amid rising dementia prevalence.
2025-09-15 16:54:00



showbiz sport money travel garden news tech health science business politics culture environment